Current Size: 100%

SR-BI is crucial for the metastatic phenotype in melanoma

Metastatic melanoma is characterised by metabolic abnormalities. But how aggressive tumor behaviour is altered by metabolic state remains ill understood.  Researchers from Vienna in collaboration with the LBI-CR now report high-density lipoprotein (HDL) receptor SR-BI expression can predict melanoma progression in patients. The metastasis-associated epithelial-to-mesenchymal transition (EMT) was perturbed by SR-BI knockdown, but not functional inhibition of its cholesterol transporting capacity. When human metastatic melanoma clinical specimens were analyzed for the abundance of SR-BI and STAT5 protein, a positive correlation was found and loss of SR-BI resulted in decreased glycosylation, reduced DNA binding and target gene expression of STAT5. Implications: High SR-BI expression in melanoma is linked with increased cellular glycosylation and hence is essential for a metastasis specific expression signature.
This report was now published in the journal Molecular Cancer Research